Characterization of Immunosuppressive Signing of Cervical Cancer (Xac03)
Infection with Human Papillomavirus high-risk Human (HR-HPV) is the main factor of risk of cancer of the cervix. Recent studies show that cancers linked to infection with HR-HPV are associated with immunosuppression and lack of T cell response Such mechanisms would promote progression to cancer and progression of it . Various factors such as an increase of regulatory T cells, the presence of myeloid cells and suppressor of defects in the signaling pathway Toll Like Receptor (TLR) may have a key role in these immunosuppression mechanisms. At this stage of knowledge, a better characterization of local and systemic immunosuppressive signing of cervical cancer is needed. The results should have a significant medical impact for the identification of new prognostic markers and new therapeutic targets for the treatment of patients with cervical cancer.
The aim of this research project is to define the signing of immunosuppressive cancer cervix and analyze the different mechanisms involved in this immunosuppression.
研究概览
研究类型
注册 (预期的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名：Urielle DESALBRES, Director
- 电话号码：04.91.38.27.47
- 邮箱：drci@ap-hm.fr
研究联系人备份
- 姓名：Xavier CARCOPINO, PU-PH
- 邮箱：xavier.carcopino@ap-hm.fr
学习地点
-
-
-
Marseille、法国、13354
- Assistance Publique Hopitaux De Marseille
-
接触：
- Urielle DESALBRES, Director
- 电话号码：04.91.38.27.47
- 邮箱：drci@ap-hm.fr
-
接触：
- Xavier CARCOPINO, PU-PH
- 邮箱：xavier.carcopino@ap-hm.fr
-
首席研究员：
- Xavier CARCOPINO, PU-PH
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- The women presenting for initial therapeutic management of cervical cancer
- Elderly patients over 18 years
- Patients beneficiary of a social security scheme
- Pregnant women can not participate in this study
- Women known to be HIV positive will not participate in this study
Exclusion Criteria:
- Patients with a recurrence of a treaty cervical cancer
- Patients with a history of pelvic radiotherapy
- Patients unable to receive informed about the progress and objectives of the study
- Patients not receiving a social security scheme
- Patients who have not signed informed consent
- Immunocompromised patients and pregnant women
学习计划
研究是如何设计的？
设计细节
- 主要用途：诊断
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：patients with invasive cervical cancer
Blood sample
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Lack of tumor emboli histological analysis
大体时间：60 months
|
Patients with good prognosis of cervical cancer
|
60 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.